Acute myeloid leukaemia (AML) can be divided into two subtypes: de novo, when it is not caused by chemotherapy or another preceding haematological condition, and secondary, when it is derived from such a condition. AML is a group of neoplastic disorders characterized by an increase in the number of immature myeloid cells in the bone marrow with or without involvement of the peripheral blood. As a consequence, a bone marrow failure syndrome, producing anaemia, granulocytopenia and thrombocytopenia, with its clinical manifestations characterized by dyspnoea and weakness, infections and bleeding, is seen. If untreated, AML is usually fatal within weeks from the time of diagnosis. AML is more frequently seen in older adults. The incidence in the US is 3.5 cases per 100 000, being higher in patients over the age of 65 years compared with younger patients (15.9 vs 1.7, respectively), and causes approximately 2.1% of all cancer deaths in the US, with an annual death rate of 3.2 per 100 000 in 2007.
Editor Note: Journal of Cancer Clinical Trials
Editor Note: Journal of Cancer Clinical Trials
Review Article: Journal of Cancer Clinical Trials
Review Article: Journal of Cancer Clinical Trials
Commentary: Journal of Cancer Clinical Trials
Commentary: Journal of Cancer Clinical Trials
Editorial: Journal of Cancer Clinical Trials
Editorial: Journal of Cancer Clinical Trials
Posters & Accepted Abstracts: Journal of AIDS & Clinical Research
Posters & Accepted Abstracts: Journal of AIDS & Clinical Research
Scientific Tracks Abstracts: Journal of AIDS & Clinical Research
Scientific Tracks Abstracts: Journal of AIDS & Clinical Research
Accepted Abstracts: Journal of AIDS & Clinical Research
Accepted Abstracts: Journal of AIDS & Clinical Research
Posters & Accepted Abstracts: Journal of Advanced Practices in Nursing
Posters & Accepted Abstracts: Journal of Advanced Practices in Nursing
Posters & Accepted Abstracts: Journal of Advanced Practices in Nursing
Posters & Accepted Abstracts: Journal of Advanced Practices in Nursing
Journal of Cancer Clinical Trials received 95 citations as per Google Scholar report